Business
Ludwig Enterprises Developing New Partnerships to Fuel Growth
Ludwig Enterprises Developing New Partnerships to Fuel Growth.
About this update from Ludwig Enterprises, Inc.
[{"type":"text","content":"SPARKS, NV / ACCESSWIRE / March 16, 2023 / Ludwig Enterprises, Inc. (Ludwig - The Genomics Language Company ™) is in discussions with several organizations that should contribute significantly to the company's revenue growth. The Ludwig team has entered into discussions with a foreign developer of nutraceutical products to sell their products in the United States. They are also in discussions with an organization to conduct a diabetes clinical study utilizing mRNA Inflammatory Index™ to measure biomarkers for inflammation related to diabetes and its complications such as diabetic neuropathy.The World Health Organization estimates that there are 422 million people with diabetes world-wide and it is estimated that 1.5 million deaths annually are directly attributable to the illness."While it is too early to release any details of the budding partnership on diabetes," says Ludwig's Chief Science Officer Marvin S. Hausman MD, "we are extremely excited about the potential to positively impact the health of so many people. The mRNA Inflammatory Index™ may enable physicians to assess early on the potential impact of the diabetic condition, and thereby design treatments to reduce future complications, such as neuropathy and nephropathy."To date Ludwig's subsidiary Precision Genomics has collected and is testing over 1700 samples from 28 different medical clinics along with detailed patient medical history. The company is receiving over 100 samples each month. Ludwig Enterprises has IRB approval for a study using the mRNA Inflammatory Index to possibly confirm early presence of bladder cancer and perhaps even detect bladder cancer recurrence. The developing diabetes partnership could significantly increase the number of samples the company is testing with a major focus on another life-threatening disease."The potential licensing agreement with a foreign nutraceutical developer would immediately expand our product line," said Luke Fannon the companies Chief Marketing Officer. "The US Supplement and Nutraceutical market is growing at an estimated 8.9% annually and Ludwig Enterprises will be a major contributor and our potential partnership could fuel significant revenue growth in the US."About Ludwig Enterprises, Inc.Ludwig Enterprises, Inc. is a healthcare holding company focused o...